A schizophrenia-linked mutation in PIP5K2A fails to activate neuronal M channels
- 285 Downloads
Evidence for an association between phosphatidylinositol-4-phosphate 5-kinase II alpha (PIP5K2A) and schizophrenia was recently obtained and replicated in several samples. PIP5K2A controls the function of KCNQ channels via phosphatidylinositol-4,5-bisphosphate (PIP2) synthesis. Interestingly, recent data suggest that KCNQ channels suppress basal activity of dopaminergic neurons and dopaminergic firing. Activation of KCNQ accordingly attenuates the central stimulating effects of dopamine, cocaine, methylphenidate, and phenylcyclidine.
The aim of this study was to explore the functional relevance of PIP5K2A, which might influence schizophrenic behavior.
Materials and methods
Here, we study the effects of the neuronal PIP5K2A on KCNQ2, KCNQ5, KCNQ2/KCNQ3, and KCNQ3/KCNQ5 in the Xenopus expression system.
We find that wild-type PIP5K2A but not the schizophrenia-associated mutant (N251S)-PIP5K2A activates heteromeric KCNQ2/KCNQ3 and KCNQ3/KCNQ5, the molecular correlate of neuronal M channels. Homomeric KCNQ2 and KCNQ5 channels were not activated by the kinase indicating that the presence of KCNQ3 in the channel complex is required for the kinase-mediated effects. Acute application of PI(4,5)P2 and a PIP2 scavenger indicates that the mutation N251S renders the kinase PIP5K2A inactive.
Our results suggest that the schizophrenia-linked mutation of the kinase results in reduced KCNQ channel function and thereby might explain the loss of dopaminergic control in schizophrenic patients. Moreover, the addictive potential of dopaminergic drugs often observed in schizophrenic patients might be explained by this mechanism. At least, the insufficiency of (N251S)-PIP5K2A to stimulate neuronal M channels may contribute to the clinical phenotype of schizophrenia.
KeywordsPIP2 KCNQ Schizophrenia Dopamine Addiction Channel Mutation Potassium Kinase
The work of Olga Fedorenko was supported by INTAS YS Fellowship (Ref. No. 04-83-3764). We thank Jasmin Bühringer for helping in the preparation of the manuscript.
Conflict of interest statement
The authors declare that, except for income received from their primary employer, no financial support or compensation has been received from any individual or corporate entity over the past 3 years for research or professional service, and there are no personal financial holdings that could be perceived as constituting a potential conflict of interest.
- Hansen HH, Andreasen JT, Weikop P, Mirza N, Scheel-Krüger J, Mikkelsen JD (2007) The neuronal KCNQ channel opener retigabine inhibits locomotor activity and reduces forebrain excitatory responses to the psychostimulants cocaine, methylphenidate and phencyclidine. Eur J Pharmacol 570:77–88PubMedCrossRefGoogle Scholar
- Lang F, Klingel K, Wagner CA, Stegen C, Warntges S, Friedrich B, Lanzendorfer M, Melzig J, Moschen I, Steuer S, Waldegger S, Sauter M, Paulmichl M, Gerke V, Risler T, Gamba G, Capasso G, Kandolf R, Hebert SC, Massry SG, Broër S (2000) Deranged transcriptional regulation of cell-volume-sensitive kinase hSGK in diabetic nephropathy. Proc Natl Acad Sci U S A 97:8157–8162PubMedCrossRefGoogle Scholar
- Marquez MF, Ramos-Kuri M, Hernandez-Pacheco G, Estrada J, Fabregat JR, Perez-Vielma N, Gómez-Flores J, González-Hermosillo A, Cárdenas M, Vargas-Alarcón G (2006) (KCNQ 1 (KvLQT1) missense mutation causing congenital long QT syndrome (Jervell–Lange–Nielsen) in a Mexican family). Arch Cardiol Mex 76:257–262PubMedGoogle Scholar
- Martire M, D'Amico M, Panza E, Miceli F, Viggiano D, Lavergata F, Iannotti FA, Barrese V, Preziosi P, Annunziato L, Taglialatela M (2007) Involvement of KCNQ2 subunits in (3H)dopamine release triggered by depolarization and pre-synaptic muscarinic receptor activation from rat striatal synaptosomes. J Neurochem 102:179–193PubMedCrossRefGoogle Scholar
- Schwab SG, Knapp M, Sklar P, Eckstein GN, Sewekow C, Borrmann-Hassenbach M, Albus M, Becker T, Hallmayer JF, Lerer B, Maier W, Wildenauer DB (2006) Evidence for association of DNA sequence variants in the phosphatidylinositol-4-phosphate 5-kinase IIalpha gene (PIP5K2A) with schizophrenia. Mol Psychiatry 11:837–846PubMedCrossRefGoogle Scholar